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Summary.-The sera from patients with advanced cancer were tested for their speci-
fic inhibitory effects on the cytotoxicity of autologous lymphocytes on tumour cells
in a microculture assay. By adding a standard volume of the sera to suspensions of
well-washed lymphocytes the inhibitory effect was quantitated by comparison with
the effect of normal allogeneic serum. Significant levels of inhibitory activity were
detected in 7 patients (one massive primary melanoma, 4 with disseminated mela-
noma, one with metastatic hypernephroma and one with a recurrent leiomyosar-
coma). The patient with a massive primary melanoma was treated by extensive
surgical excision. This procedure was associated with the rapid and complete
disappearance of the serum inhibitory effect. In the other cases surgical inter-
vention was minimal and the serum inhibitor was unaffected. All 6 of these patients
were then immunized with irradiated autologous tumour cells and the serum inhibi-
tory activity assayed. In 5 cases the serum inhibitor rapidly became undetectable
after a single immunization. The one patient who failed to respond in this manner
had very extensive disease and died within 2 weeks of the study. Repeated monthly
immunization in the case of recurrent leiomyosarcoma was associated with the
maintenance of the serum inhibitory activity at very low levels and with good cliiiical
progress. The response to a single immunization is transient, the inhibitor becoming
detectable again at 14-21 days. The possible role of circulating antigen in this serum
inhibitory activity is discussed, as is the potential value of assaying the sera of cancer
patients for serum inhibitory activity, as a means of monitoring the effects of treat-
ment.
IF immunological techniques are to be
effective in the treatment of cancer,
methods will be needed for assaying the
reactions of patients to antigens on their
own tumour cells and for monitoring the
effects of treatment on these reactions.
Hellstrom and her colleagues (1971) have
shown that the peripheral blood lympho-
cytes from patients with a variety of
tumours are capable of killing the appro-
priate target cells in tissue culture in a
specific manner. Furthermore, they have
indicatedthattheserum fromthesepatients
is capable of " blocking " this cytotoxic
reaction in a similarly specific fashion.
Currie and Basham (1972) have shown
that the cytotoxic effects of peripheral
blood lymphocytes from patients with
advanced cancer were dramatically in-
creased by extensive washing. Further-
more, this newly exposed cytotoxic effect
was inhibited by the addition of the
patients' serum to the lymphocyte suspen-
sion. There was also suggestive evidence
for a clinical correlation between extent
of disease and presence of this specific
serum inhibitor. In patients with small
primary malignant melanomata the serum
inhibitor was undetectable whereas in
those with large primary tumours or
metastatic disease it was found readily. It
was postulated that antigenic determi-G. A. CURRIE
nants from the cell surface are constantly
being shed by a tumour and leak into the
extracellular fluid and serum. There,
possibly complexed with antibody or
other proteins, such substances act as
potent inhibitors of antitumour cell-
mediatedimmunereactions. Furthermore,
the concentration of this inhibitory
material in the peripheral blood may well
reflect the extent of the disease and its
presence in the serum might be of diag-
nostic value.
In earlier studies of the effects of
autoimmunization of patients with dis-
seminated melanoma with irradiated
tumour cells we (Currie, Lejeune and
Fairley, 1971) were able to demonstrate
increases in the cytotoxic effects of their
peripheral blood lymphocytes when tested
on autologous tumour cells. These find-
ings can be re-interpreted in view of the
demonstration of specific serum inhibitors
as showing that the immunization proce-
dure had abolished, or at least reduced,
the levels ofcirculating inhibitor.
This communication describes experi-
ments which attempt to quantitate the
effects of active immunization with irra-
diated tumour cells (with or without
B.C.G.) on the serum inhibitory material
in a small group of patients with dis-
seminated cancer.
MATERIALS AND METHODS
Tumour cell cultures.-Fresh biopsy
specimens were obtained- at operation and
the samples washed and trimmed. The
tumour fragments were disaggregated by
agitation in 0.1% trypsin and 0-1% colla-
genase solution for 30 minutes. After wash-
ing in medium 199 containing DNAase the
cells were suspended in RPM1 1640 (Biocult)
containing 10% heat inactivated foetal
bovine serum and cultured in disposable
plastic flasks. Tumour cells obtained either
by trypsinization or by mechanical means
were stored under liquid nitrogen in the
presence of 10% dimethyl sulphoxide.
Lymphocyte preparations.-Defibrinated
peripheral venous blood was obtained from
the patients and from normal healthy
volunteers. After 20 minutes incubation
with 200 mg of carbonyl iron powder each
20 ml of blood was allowed to sediment after
the addition of 6 ml of 1% methyl cellulose
(Methocel) innormalsaline. After20minutes
sedimentation the lymphocyte-rich super-
natant was withdrawn and the lymphocytes
were washed 6 times. The washing consisted
of the addition of 25 ml of medium 199, re-
suspension and then centrifugation at approx-
imately 1000 rev/min for 5 minutes. This
washing step was performed at room tempera-
ture. Finally, thelymphocytes were counted
in a haemocytometer and made up in RPM1
1640 plus foetal bovine serum.
Lymphocyte microcytotoxicity assay.-
Tumour cells were obtained from stock
cultures by trypsinization (0-1% crystalline
trypsin in medium 199), washed once with
medium 199 and then suspended in RPM1
1640 + foetal bovine serum at approximately
104 per ml. They were then added in 10 ,li
aliquots into the wells of disposable plastic
culture plates (Falcon 3034) and cultured
under 5% CO2 in air at 37TC overnight. The
plating efficiency of recently cultured human
tumour cells is extremely variable and it was
not possible to predict with any degree of
accuracy the number oflive cells attaching in
each well. The following morning the plates
were inverted and examined under phase
contrast and the number of cells attached in
each well counted. From the mean number
of cells in each well the concentration of
lymphocytes needed to provide a final
lymphocyte tumour cell ratio in each 10 ,ul
of 400 :1 was calculated. The lymphocyte
suspensions were adjusted to this concentra-
tion and contained 5% serum from either
healthy normal volunteers or the patients
under study. The test was carried out as
described previously (Currie and Basham,
1972), and results expressed similarly as per
cent cytotoxicity. Furthermore, any inhibi-
tory effect of the added patients' serum was
expressed as a percentage reduction of the
cytotoxic effect obtained in the presence of
control serum.
Active immunotherapy
Autologous tumour cells.-All the patients
immunized were inoculated with autologous
tumour cells. The cells used for this purpose
were irradiated in a 6OCO source to a total
dose of 12-5 krad. Thedetails oftheimmun-
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TABLE I. List ofPatients Examined and the Type of Active Immunization Protocol
Employed in Each Case
Diagnosis and clinical details
Hypernephroma, locally invasive with lung
and bone metastases
Malignant melanoma, with multiple large
subcutaneous metastases mainly on trunk
and neck
Malignant melanoma with cutaneous and
hepatic metastases
Massive primary malignant melanoma of
the back with regional node metastases
Malignant melanoma with massive
involvement of lymph nodes in the right
inguinal region and multiple pulmonary
metastases
Recurrent duodenal leiomyosarcoma with
massive involvement of peritoneum and
abdominal wall
Treated after excision of part of the
lesion
ization procedure are listed separately for
each case in Table I.
B.C.G.-In some of these cases B.C.G.
was incorporated into the tumour cell suspen-
sion as described by Sokal and his colleagues
(Sokal, Aungst and Han, 1972). The pre-
paration used was percutaneous vaccine
(Glaxo), and the details of each case are
listed in Table I. When B.C.G. was admixed
with the autologous cell suspension the
resulting vaccine was administered intra-
dermally in one limb in 8 distinct sites.
RESULTS
The detailed results ofthe cytotoxicity
assays are shown in Table II. Day 0 in
the table signifies the day on which the
immunotherapy was given for the first
time. All immunizations were performed
more than 8 days after any surgery. None
of the patients had received any other
form oftreatment before being immunized.
Cytotoxicity of lymphocytes
In all cases studied there was signifi-
cant cytotoxicity of the patient's well-
washed lymphocytes on the appropriate
target cells before immunization. In Cases
Me 327 and Me 331 the autologous cultures
Site and type of immunotherapy
1-3 x 108 autologous tumour cells
subcutaneously in all four limbs
5 x 108 autologous tumour cells
subcutaneously in the right upper arm and
both thighs
108 autologous tumour cells in left upper
arm intradermally in 8 sites with 0 2 mg
B.C.G.
5 x 107 trypsinized autologous tumour
cells in right upper arm intradermally in 8
sites with 0 1 mg B.C.G.
3 x 107 trypsinized autologous tumour
cells in left upper arm in 8 sites
intradermally with 0*3 mg B.C.G.
Day 0: 108 trypsinized cells in left upper
arm intradermally in 8 sites with 0 4 mg
B.C.G.
Day 28: 108 trypsinized cells in the right
upper arm intradermally in 8 sites with no
B.C.G.
Day 56: 108 trypsinized cells in left upper
arm intradermally in 8 sites with 0 1 mg
B.C.G.
were not of adequate quality and there-
fore the lymphocytes were tested on
allogeneic melanoma cultures. As indi-
cated previously (Currie and Basham,
1972) the cytotoxic effects of the lympho-
cytes from melanoma patients cross-react
on allogeneic melanoma cells. The inclu-
sion in this study of normal allogeneic
donors and the specificity controls con-
tinue to support earlier conclusions con-
cerning the specificity of the reactions
(Currie and Basham, 1972). The target
cells used for this series of experiments
were not established cell lines. They
consisted in all cases of early subcultures
following the initial explantation of the
tumour cells. Morphological and growth
criteria were used to determine whether
or not the cells were tumour cells. All
cultures with an obviously fibroblastic
component were rejected. Furthermore,
contamination with macrophages, a fre-
quent problem associated with primary
cultures, was avoided by trypsinization
of the cultures before inoculation into the
microtest plates. Macrophages are not
removed from the plastic substratum by
such trypsinization.
Case no.
HYP 27
Me 307
Me 327
Me 329
Me 331
LMS1
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TABLE II.-Cytotoxic Effects of Patients' Lymphocytes on Tumour Cell Microcultures.
The Results are Expressed as the Mean Number ofCells Remaining in each Well ± one
Standard Deviation and as a Percentage Cytotoxicity. The effects of Added Patients'
Sera are Expressed as a Percentage Inhibition of the Lymphocyte Cytotoxicity Obtained
in the Presence of Normal Serum
Diagnosis Target Lymphocytes
and details cells added
Cells
per
well ±
Serum added S.D.
Serum
Cyto- inhi-
toxic bition
index %
HYP 27 Hypernephroma
with lung and
bone metastases
Malignant
melanoma with
cutaneous
metastases
Malignant
melanoma with
extensive
cutaneous and
hepatic
metastases
Malignant
melanoma,
massive primary
tumour with
regional node
metastases
Leiomyosarcoma
recurrence with
peritoneal
metastases
HYP 27
HYP 27
HYP 27
HYP 27
HYP 27
HYP 27
HYP 27
HYP 27
Me 307
Me 307
Nil
Day 0 HYP 27
Day 0 HYP 27
Control
Nil
Day 8 HYP 27
Day 8 HYP 27
Day 8 HYP 27
Nil
Day 7 Me 307
Me 307 Day 7 Me 307
Me 307 Day 7 Me 307
Me 328
Me 328
Me 328
Me 328
Me 329
Me 329
Me 329
Me 329
Me 329
Me 329
Me 329
Me 329
Me 329
Me 328
Me 328
Me 328
Me 328
LMS,
LMS,
LMS,
LMS,
LMS,
LMS1
LMS1
LMS,
LMS1
LMS,
Me 328
Me 328
LMS1
LMS1
LMS,
Nil
Day 7 Me 327
Day 7 Me 327
Day 7 Me 327
Nil
Day 7 Me 327
Day 7 Me 327
Day 7 Me 327
Control
Nil
Day 8 Me 329
Day 8 Me 329
Day 8 Me 329
Nil
Day 8 Me 329
Day 8 Me 329
Day 8 Me 329
Nil
Day 0 LMS,
Day 0 LMS,
Control
Nil
Control
Day 14 LMS1
Day 14 LMS1
Day 14 LMS1
Nil
Day 28 LMS1
Day 28 LMS1
Nil
Day 28 LMS1
Nil
Day 56 LMS1
Day 56 LMS1
Nil
Control
Control
Day 0 HYP 27
Control
Control
Control
Day 0 HYP 27
Day 8 HYP 27
Control
Control
Day 0 Me 307
Day 7 Me 307
Control
Control
Day 0 Me 327
Day 7 Me 327
Control
Control
Day 0 Me 327
Day 7 Me 327
Control
Control
Control
Day 0 Me 329
Day 8 Me 329
Control
Control
Day 0 Me 329
Day 8 Me 329
Control
Control
Day 0 LMS,
Control
Control
Control
Control
Day 0 LMS,
Day 14 LMS1
Control
Control
Day 28 LMS1
Control
Control
Control
Control
Day 56 LMS,
Control
107± 8
89± 9
122± 9
119± 8
103± 6
75± 7
96± 8
109± 9
227±15
16±10
17%
-14%
- 8%
27%
7%
- 6%
93%
108±13 53%
15± 4 94%
38± 2
14± 4
26± 4
13± 3
87± 4
33± 6
40± 2
28± 3
88± 3
18± 2
7± 2
14± 3
7± 2
31± 3
8± 1
14± 2
7± 2
198±10
56± 6
152± 9
204±10
47± 3
50± 3
21± 4
38± 5
23± 3
451 3
27± 5
30± 6
28± 2
28± 3
21± 2
9± 1
10± 1
89± 6
63%
32%
66%
62%
54%
68%
- 1%
61%
22%
61%
74%
55%
.77%
72%
23%
3%
- 6±
55%
19%
5.1%
40%
33%
0%
57%
52%
Patient
Immunized
with auto-
logous cells
only
Me 307
Immunized
with auto-
logous cells
only
Me 327
Immunized
with auto-
logous cells
and B.C.G.
Me 329
Immunized
with auto-
logous cells
and B.C.G.
LMS1
Immunized
every 28 days
with auto-
logous cells
and B.C.G.
100
75
100
57
0
50
0
13
0
64
0
26
0
68
60
8
17
8
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Diagnosis Target Lymphocytes
and details cells added
NIalignant,
melanoma with
vymph node +-
tilng metastases
Massive primary
malignanit mela-
noma with no
clinical evidence
of metastases.
Treated by wide
local excision on
Day 0.
No other
treatment
LMS,
LMS1
OC14
Me 328
Me 328
MIe 328
Me 328
Me 328
Me 328
Me 328
AMe 332
Me 332
MAe 332
C14
Ovarian
adeno-
carcinoma
Me 328
Me 328
AMe 328
Me 328
Me 332
MIe 332
Me 332
MIe 332
Me 332
MIe 332
Mie 332
Mte 332
AMe 332
MIe 332
M1e 332
Day 74 LMS,
Day 74 LMS,
Nil
Day 74 LAIS
Nil
Cointrol
Day -8 Me 331
Day- 8Ae 331
Nil
Day 0 Me 331
Day 0 Me 331
Nil
Day 0C Me 331
Day 0 Me 331
Nil
Dav 7 Me 331
Nil
Day 7 Me 331
Day 7 Me 331
Day 7 Me 3s31
Nil
Day 7 AMe 331
Day 7 Me 331
Day 7 Me 331
Nil
Day 14 Me 331
Day 14Me 331
Nil
Control
AMe 335
AMe 335
AMe 332 AMe 335
Me 332 ate 335
l\Ie 332 Me 335)
Cells
per
well
-
Serum a(lded S.D.
Control
Day 74 LMS,
Control
Control
Control
Control
Control
Day-8 A8e 33l
Control
Control
Day 0 Me 331
Control
Control
Day 0 Me 331
Control
Control
Control
Control
Day -4 Me 331
Day+7 AMe 331
Control
Control
Day-4 Me 331
Day+ 7 Me 331
Control
Control
Day 14 AMe 331
Control
CoIntirol
Control
Day 0
Day 4
Day 6)
Day 11
56±
61 2-
69±
70±
16±
14±
5±
12±
43"'
22±
36±
64±
18±
44±
49-4-
7
7
3
3
2
2
2
3
4
3
6
3
4
3
4)
48± 4
25-4 3
41 -" 5
25± ± 2
136± 7
65- 6
112 + 8
74 ' 5
90±43
34± 2
62± 8
71 7 7
74 z 6
33± 4
65± 8
Cyto-
toxic
index
37%
32%
0
13%
700%
2000
490%
16%
72%
32%
40
48%
14-5%
48%
5200
17.50%
46%
6200
310%
540
8%
Serum
inhi-
bition
15
67
67
57
70
0t
66
12 -5
5)
84
55± 7 23 0/ 58
49± 4 31% 42
372- 5 48% 8
Inhibitory effect of autologous serum
All the patients studied had advanced
disease. The inhibitory effects of their
sera on autologous lymphocyte cyto-
toxicity were measured before immuniza-
tion. The lymphocytes tested in this
system were all subjected to extensive
washing before use because of previous
experience (Currie and Basham, 1972)
which indicated that the lymphocytes
from patients with extensive disease were
cytotoxic only after such a washing step.
Significant inhibition of the cytotoxic
effects of autologous lymphocytes on the
appropriate target cells was detected in
all cases. The specificity of this inhibi-
tory material was as described previously
(Currie and Basham, 1972). In this
study the inhibitory effects of autologous
serum were also assayed in two cases of
malignant melanoma on allogeneic target
cells. It can be seen that in Case Me 329
the inhibitory effect of Day 0 serum was
64% when tested on autologous tumour
cells but only 260% when tested on allo-
geneic melanoma cells. There are cross-
reacting antigens (Currie and Basham,
1]972) on the cells of malignant melanoma
but quantitative differences in antigenic
expression in different cell populations
TABLE II cont.
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Patient
Immunized
every 28 days
with autologous
cells aild B.C.G
AMe 331 A
Immwilizedi
-with auto-
logous cells
and B.C.G.
Me 335G. A. CURRIE
may be involved. The crude quantitative
estimation of the inhibitor may provide a
means ofmonitoring the effects ofimmuno-
therapy, but before such a conclusion can
be reached it is important to know that
massive changes in its concentration in the
serum do not occur spontaneously. In
Case Me 331, the serum inhibitor 2 days
after surgical biopsy was 67%. Measured
again on the same test cells at Days -4
and Day 0 the inhibitory effects were 70
and 670% respectively. This reproduci-
bility indicates that the level of serum
inhibitor is constant over a short period
in a patient with extensive disease. All
6 of the patients who were subsequently
immunized with tumour cells had very
widely disseminated disease and the sur-
gical treatment they received consisted
mostly of biopsies or at most partial
resection. This surgicalintervention made
little impact on the patients' overall
tumour burden and, as was seen in Case
Me 331, the levels of serum inhibitor were
unaffected. Whether or not there are any
massive acute changes in serum inhibitory
activity following total surgical ablation
of a tumour was investigated in a separate
patient (Case Me 335) who did not receive
any form ofimmunization. This man had
a massive primary melanoma measuring
17 x 25 cm with no clinical evidence of
regional or distant metastatic spread.
The tumour was excised widely and the
wound skin-grafted. Clinically and histo-
logically there was total removal of the
tumour. His serum was assayed for
inhibitory activity on the day ofoperation
and on several occasions in the following
2 weeks. These results are shown in
Table II and Fig. 4 and indicate that total
tumour resection is associated with rapid
and complete disappearance of the inhibi-
tory activity from the serum.
Effect of immunization on the serum
inhibitor
Each patient received the immuniza-
tion protocol listed in Table I and the
serum effects on lymphocyte cytotoxicity
were measured after one week, except in
100O
75 -
z
0
I-
z
25-
00 7 14
DAYS
FIG. 1.-Inhibitory effects of patients' sera on auto-
logouslymphocyte cytotoxicity assayed before and
after immunization with autologous irradiated
tumour cells. The top line, which rose after
immunization, shows the result obtained in the
patient with metastatic hypernephroma (HYP
27).
Case LMS1 where it was measured at 14
days and thereafter at Days 28, 56 and 74.
Theseresults areshown in Table II andFig.
1. Day 0 is the day on which the immuni-
zation started. In all cases except one
there was a dramatic fall in the serum
inhibitory effect detectable after one week.
In Case LMS1 the inhibitor had dis-
appeared at Day 14. This was measured
again at Day 28 when it had increased to
17%. Re-immunization at Days 28 and
56 was associated with the maintenance of
his serum inhibitor at minimal levels.
The one exception to the effects of
immunization was the case of hyper-
nephroma (HYP 27). This patient had a
large hypernephroma at the lower pole
of his right kidney which was extensively
invasive into the inferior vena cava, the
duodenum and the retroperitoneal space.
There were also lytic metastases in the
ribs and lumbar vertebrae. The tumour
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10 Cells
BCG +
10 Cells
Ir
LMSI
20 60 80
DAYS
FrIc. 2. Inlhibitory effect of serum on autologous lymphocyte cytotoxicity in a patienit with recurrent
leiomyosaicoma before and dturing monthly immunization (-' B.C.G.).The inhibitoiry activitv
was measured at Days (), 14, 28, 56 an(d 74.
was excised and following a stormy
post-operative course he was immunized
12 days after surgery. Before immuniza-
tion his cytotoxic lymphocytes, tested on
autologous tumour cells, were feeble,
giving a cytotoxic index of 17%. Assess-
ment of the serum inhibitory effect of
Days 0 and 8 tested on Day 8 lymphocytes
indicated that the serum inhibitor rose
from 75% on Day 0 to 100% on Day 8.
The clinical course ran a rapid downward
path; he died with extensive metastases
Biopsy
100
z
0
co
I
z
0o
50_
o
14 days after the immunization. It is
unlikely that the immunization procedure
had contributed to the progression of the
disease in that there was evidence of
further metastatic spread and growth
before immunization. The patient with a
recurrentleiomyosarcoma ofthe duodenum
(LMS1) did well following immunization
(Fig. 2). In this case he was immunized
at monthly intervals. At the original
surgical excision of part of the recurrent
tumour mass there was extensive seedling
Cells + BCG
Me 331
-8 -6 -4 -2 0 2 4 6 8 10 12 14
DAYS
FIG. 3.-Serial assays of ser-um inhibitory activity in a patient writh disseminate(l maligniant mela-
noma before andcl after a single immunizationi with tumouir cells and B.C.G. The assay was
performed on sera obtaine(d on Days -8, -4, 0, 7 and 14. The inhibitory activity was relatively
constant (hitring andl after surgery and before immtinization. After immunization it (iecrease(1 to
zero at Day 7 buit re-appear-ed by Day 14.
BCG +
10 Cells
z
0
H-
z
-0-
3S1Z Me¢335
0
-o 50
z
0-
01 1
0 5 10
DAYS
Excision
1m. 4.-Serial assays of serum inhibitory activity in a patient with a massive primary melanoma
following total surgical ablation of the tumour, showing rapid and total disappearance of the
activity.
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stitute the " blocking " material described
by Hellstrom et al. (1971) in the serum of
cancer patients.
Recognition of the existence of these
seruminhibitoryfactors andtheirapparent
specificity to tumour type may have
clinical implications. If, as seems prob-
able, the antigens on tumours are specific
to the organ of origin and totally cross-
reactbetweentumours ofsimilardiagnosis,
then the quantitative analysis of such
antigenic material inthe serum may be of
value for the clinical management of
cancer patients.
The present study has employed an in
vitro method for the detection and quanti-
tation ofthe seruminhibitory material in a
small series of patients with advanced
tumours. Serum inhibitory effects were
detectable in all the cases. Following
active immunotherapy with irradiated
autologous tumour cells with or without
B.C.G., the inhibitory activity was drastic-
ally reducedin all cases but one (HYP 27).
In this exceptional case there was, if
anything, a rise in serum inhibitor which
accompanied a dramatic decline in his
clinical condition, with the growth of
extensive metastatic disease. If, as we
have postulated previously, circulating
antigen is capable of inhibiting tumour-
directed cell-mediated immunity then the
addition of further tumour antigen, in
the form of the tumour cell vaccine, may
well add to an already overloaded pool of
antigen and thus be unable to evoke any
kindofimm'nological response. However,
prediction ofwhich case is likely to do this
and which to respond favourably, with a
decline in serum inhibitory activity, is at
present impossible. The initial inhibitory
effect of the Pay 0 serum in this case was
extremely hikh and the patient's tumour
burden was massive. His lack ofresponse
may have been dictated by the initial high
level ofinhibitory activity.
Sinkovics andhis colleagues (Sinkovics,
Cabiness and Shullenberger, 1972) have
described three patients with disseminated
sarcomata whose lymphocyte cytotoxicity
and serum " blocking " factors were
examined before and after treatment with
cytosine arabinoside. All three possessed
cytotoxic lymphocytes and serum " block-
ing" factors. Followingthechemotherapy
these inhibitors became undetectable al-
though the cytotoxic effects of the
lymphocytes were unaffected. In one
case the disappearance of the serum
inhibitor was associated with temporary
tumour regression. Two ofthese patients
had previously received irradiated allo-
geneic sarcoma cells as a form ofimmuno-
therapy but the authors did not report
any effect of this procedure alone on the
serum inhibitory activity. Sinkovics et
al. (1972) postulated that the cytosine
arabinoside had abolished " blocking acti-
vity " by interfering with the synthesis
of specific antibody, thus preventing the
formation of " blocking " immune com-
plexes. These authors examined sera for
this " blocking " activity by pre-incuba-
tion ofthe target cells with the test serum
before addition of the lymphocytes, as do
Hellstrom et al. (1971) in their assay
system. Tested in this manner it is
feasible that inhibitory effects would be
detected only when specific antibody,
probably complexedwithantigen, waspre-
sent. In our assay system the test serum
is directly incorporated in the lymphocyte
suspension and no pre-incubation step is
involved. Thus it could be argued that,
in the test format used by us, inhibitory
activity of excess antigen, as well as
immune complex would be detected. It
is of interest that Sinkovics and his
colleagues were able to detect " blocking "
serum activity in only about halfthe cases
of disseminated disease. It may well be
that with progression ofthe tumours, with
its attendant release of large quantities
of tumour antigen, immune complexes
would be overwhelmed and a condition
of antigen excess would prevail, in which
case the " blocking " activity may not
be detectable in an assay in which the
serum is pre-incubated with the target
cells. Thus, in some patients with estab-
lished disease the serum inhibitor may be
circulating immune complex, whereas in
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those whlere the tumour burden is more
massive it may be antigen relatively free
of specific antibody and detectable only
in assays in which the serum is included
in the reaction mixture. Baldwin and his
colleagues (Baldwin, Price and Robins,
1972) have emphasized the critical nature
of the antigen-antibody ratio in immune
complexes which determine their in vitro
"blocking" activity, addition of excess
antigen to tumour bearing serum abolish-
ing its blocking activity. This blocking
was assayed by pre-incubation of the tar-
get cells with the test serum. Excess
antigen would tend to inhibit attachment
of immunoglobulin receptor sites to the
target cells and when the serum is dis-
carded the potential inhibitory material
is removed. It would seem rational to
restrict the term " blocking" to findings
obtained from the pre-incubation type of
assay and to use the somewhat vague
term "inhibition " to describe the effects
obtained in our inclusion assay.
How does immunization with tumour
cells lead to a reduction in serum inhibitory
effect? Presumably when the patient is
injected with tumour cells in a limb
uninvolved by tumour the regional node
chain is stimulated. Ikonopisov and his
colleagues (1970) have described the
appearance of an antibody reacting with
tumour cells in patients with malignant
melanoma following autoimmunization
with irradiated tumour cells. Preliminary
studies in these laboratories (Currie and
Basham-unpublished) have shown the
development of complement-dependent
cytotoxic antibodies in the same serum
samples in which the serum inhibitor was
undetectable following immunization. A
secondary response in the regional nodes
may result in antibody production and if,
as we have postulated (Currie and Basham,
1972), the active component of the circu-
lating inhibitor is tumour associated anti-
gen then the sudden flooding of lymph
and serum with specific antibody would
be expected to complex any free antigenic
determinant sites. The resultant immune
complex would presumably be cleared
from the circulation. Following a single
booster shot of antigen the response of
the lymph nodes would be short-lived and
continued release of antigen from the
tumour would mean that the reduction in
serum inhibitor following a single immuni-
zation is transient as the antibody is soon
swamped by antigen. The demonstration
of complement-dependent cytotoxicity in
the sera following immunization lends
weight to this hypothesis.
The disappearance of serum inhibitors
following immunotherapy provides a
rational explanation for the results des-
cribed by Currie and his colleagues (1971),
from which it was concluded that cytotoxic
lymphocytes, undetectable in patients
with advanced malignant melanoma, be-
came detectable following autoimmuniza-
tion with irradiated tumour cells. It was
shown subsequently that the lymphocytes
from patients with advanced tumours did
in fact possess cytotoxic properties but
these were manifest only after they had
been extensively washed. The apparent
affinity of the serum inhibitory material
for the lymphocyte surface led to the
postulate that its active component was
circulating tumour-associated antigen
(Currie and Basham, 1972).
The use of active immunotherapy in
the treatment of human cancer is at
present on an entirely empirical basis.
Irradiated tumour cells and B.C.G. are
the most frequently used reagents. How-
ever, the way in which they are given is
frequently based on intuition rather than
fact. Sokal and his colleagues (1972)
have attempted to introduce a rational
approach by the immunization of patients
with allogeneic cultured tumour cells and
then testing for subsequent delayed hyper-
sensitivity by the intradermal inoculation
of the same line of cells. They showed
that the inclusion of B.C.G. admixed with
the tumour cells before intradermal immu-
nization led to powerful delayed hyper-
sensitivity to cells alone. Positive res-
ponses were obtained by immunization
with as few as 5 x 107 cells.
In the present series of immunizations
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we started in two cases (HYP 27, Me 307)
with large doses (>108) of irradiated
tumour cells given subcutaneously in
multiple sites. This was based on the
earlier regimen used in this laboratory
in which the minimal dose ofcells to evoke
a response was found to be over 108 cells
(Ikonopisov et al., 1970; Currie et al.,
1974). Thisfigurewas obtainedinpatients
immunized by the subcutaneous route in
multiple sites. In this series we immu-
nized some of the patients with as few as
3 X 107 cells mixed with B.C.G. and
obtained prompt significant responses.
Examination of the serum inhibitory
activity following various immunological
treatments may well allow us to design
rational therapeutic protocols, to evaluate
different modes oftreatment and perhaps,
most important of all, allow us to deter-
mine when " immunotherapy " can be
given to best effect.
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